





# The cost-effectiveness of small-quantity lipid-based nutrient supplements for prevention of child death and malnutrition and promotion of healthy development: modelling results for Uganda

Katherine P Adams<sup>1,\*</sup> , Stephen A Vosti<sup>2</sup>, Charles D Arnold<sup>1</sup>, Reina Engle-Stone<sup>1</sup>, Elizabeth L Prado<sup>1</sup>, Christine P Stewart<sup>1</sup> , K Ryan Wessells<sup>1</sup> and Kathryn G Dewey<sup>1</sup>

<sup>1</sup>Institute for Global Nutrition, University of California, Davis, CA 95616, USA; <sup>2</sup>Department of Agricultural and Resource Economics, University of California, Davis, CA, USA

Submitted 6 May 2022; Final revision received 8 August 2023; Accepted 11 August 2023; First published online 22 August 2023

## Abstract

**Objective:** Recent meta-analyses demonstrate that small-quantity lipid-based nutrient supplements (SQ-LNS) for young children significantly reduce child mortality, stunting, wasting, anaemia and adverse developmental outcomes. Cost considerations should inform policy decisions. We developed a modelling framework to estimate the cost and cost-effectiveness of SQ-LNS and applied the framework in the context of rural Uganda.

**Design:** We adapted costs from a costing study of micronutrient powder (MNP) in Uganda, and based effectiveness estimates on recent meta-analyses and Uganda-specific estimates of baseline mortality and the prevalence of stunting, wasting, anaemia and developmental disability.

**Setting:** Rural Uganda.

**Participants:** Not applicable.

**Results:** Providing SQ-LNS daily to all children in rural Uganda (> 1 million) for 12 months (from 6 to 18 months of age) via the existing Village Health Team system would cost ~\$52 per child (2020 US dollars) or ~\$58.7 million annually. SQ-LNS could avert an average of > 242 000 disability-adjusted life years (DALYs) annually as a result of preventing 3689 deaths, > 160 000 cases of moderate or severe anaemia and ~6000 cases of developmental disability. The estimated cost per DALY averted is \$242.

**Conclusions:** In this context, SQ-LNS may be more cost-effective than other options such as MNP or the provision of complementary food, although the total cost for a programme including all age-eligible children would be high. Strategies to reduce costs, such as targeting to the most vulnerable populations and the elimination of taxes on SQ-LNS, may enhance financial feasibility.

## Keywords

Cost-effectiveness  
Uganda

Economic analysis  
Disability-adjusted life years  
Nutrient supplements

Small-quantity lipid-based nutrient supplements (SQ-LNS) were developed to prevent malnutrition among vulnerable populations. These fortified food-based products (typically including vegetable oil, peanut paste and milk powder) deliver vitamins and minerals as well as essential fatty acids and small amounts of energy (~100–120 kcal/d) and protein<sup>(1)</sup>. Since the development of SQ-LNS ~15 years ago, a strong evidence base has been established demonstrating that SQ-LNS for children 6–24 months of age reduces child mortality, stunting, wasting and anaemia and promotes healthy development in efficacy trials as well as effectiveness trials in programmatic settings<sup>(2–6)</sup>. As a result, SQ-LNS

was listed in the 2021 Lancet Series on Maternal and Child Undernutrition as an intervention with a strong evidence base supporting implementation<sup>(7)</sup>.

Alongside robust evidence of effectiveness, informed policy decisions made by governments, aid organisations and other agencies regarding their portfolios of nutrition interventions also require information about the cost and cost-effectiveness of various options. There is very limited evidence on the cost, and no evidence on cost-effectiveness, of providing SQ-LNS to young children; this study is a first step towards filling that gap. Our goal was to develop a modelling framework to estimate the potential effects, costs

\*Corresponding author: Email kpittenger@ucdavis.edu

© The Author(s), 2023. Published by Cambridge University Press on behalf of The Nutrition Society. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.



and cost-effectiveness of SQ-LNS. We estimated costs from a societal perspective rather than a narrow perspective (e.g. the perspective of programme implementers or the government) so that our estimates of cost-effectiveness would reflect not only the resources required to finance a programme to provide SQ-LNS but also the opportunity cost of caregivers' time to participate in such a programme. We selected rural Uganda for this first modelling exercise because detailed data were available on the costs of delivering a similar product, micronutrient powder (MNP), to young children in that setting<sup>(8)</sup>. Our specific objectives were to (1) develop a cost model, adapted from the MNP study, to estimate the annual total societal cost and cost per child of providing SQ-LNS, (2) develop an effectiveness model to estimate the effects of SQ-LNS on child mortality, anaemia, developmental disability, stunting and wasting and (3) translate those effects into cost per disability-adjusted life years (DALY) averted, per death averted and per case of anaemia, developmental disability, stunting and wasting averted in rural Uganda.

## Methods

We developed models to estimate the cost, cost-efficiency (cost per child) and cost-effectiveness of SQ-LNS for young children. The modelling was based on providing 12 months of daily SQ-LNS (20 g/d), beginning at 6 months of age and ending at 18 months of age, to all young children residing in rural districts of Uganda. The models were based on SQ-LNS being delivered via the existing Village Health Team (VHT) community health worker (CHW) programme. The VHTs in Uganda rely on volunteer health workers to deliver basic health and nutrition products and services, provide education and make referrals<sup>(9)</sup>. Our modelling assumed that current VHTs could, with additional monetary incentives (described below), take on the delivery of SQ-LNS to households in addition to their current activities. We modelled costs and effects over the period 2021–2031, assuming 1 year of start-up and 10 years of SQ-LNS provision.

## Costs

The cost model was developed based on an actual costing study conducted in one rural district in Uganda (Namutumba District) to estimate the cost of providing MNP to children 6–24 months of age<sup>(8)</sup>. The MNP costing study was designed to compare the cost and cost-efficiency of delivering MNP via community- *v.* facility-based platforms. The study found that the community-based platform (i.e. via VHTs) was more cost-efficient (lower cost per child reached), so we adopted the community-based platform for our SQ-LNS cost model.

We estimated economic costs from a societal perspective, meaning all costs were accounted for, regardless of who incurred them and including both the costs needed to

finance the programme and opportunity costs (e.g. the opportunity cost of caregivers' time to participate in the intervention and volunteer health worker time). Following the activity-based approach used in Schott *et al.*<sup>(8)</sup>, we estimated the cost of 1 year of start-up activities (primarily social and behaviour change communication and capacity building) and recurring activities over a 10-year time horizon, which included caregiver opportunity costs, social and behaviour change communication, logistics, capacity building, operational monitoring and evaluation costs, overhead and capital, VHT incentives, SQ-LNS product costs, SQ-LNS international shipping and handling and customs clearance and domestic SQ-LNS transport, storage and handling.

The product cost of SQ-LNS was based on the price of a carton (546 20-g sachets) of SQ-LNS published in the UNICEF Supply Catalog (<https://supply.unicef.org/s0000245.html>) in March of 2022 and adjusted to 2020 US dollars. Although local production is feasible in several African countries, we assumed international production because cost information was more reliable. The cost of SQ-LNS, which was applied to each of the 10 years of intervention, was \$33.30/carton (2020 US dollars), or \$3.06/kg, which is ~\$0.061 per 20-g sachet. International shipping and handling costs were estimated at US\$0.31/kg based on the default estimate in the FACET tool for shipping and handling of SQ-LNS on the South East Africa trade route (<http://facet4snf.org/>). Customs clearance costs were estimated at 18% for a value added tax + 33% withholdings tax<sup>(10)</sup>, or ~US\$1.01/kg. Domestic transport, storage and handling were estimated to cost US\$0.17/kg, based on the default estimate for Uganda in the FACET tool.

Given documented challenges faced by the volunteer VHT system that underlies the community-based distribution platform in rural Uganda, such as inadequate support and high rates of attrition<sup>(9,11)</sup>, we assumed that the successful addition of SQ-LNS to the products and services delivered by VHT would require a strengthening of the VHT system. Informed by a Uganda pilot performance-based incentive system<sup>(12)</sup>, we modelled an additional performance-based monetary incentive to VHT health workers of US\$0.44 per delivery of SQ-LNS, assuming SQ-LNS was delivered to households every 3 months.

All other cost estimates were adapted from the MNP costing study<sup>(8)</sup> by first identifying the base cost of each input (personnel, transport, materials, in-kind incentives) for each activity (plus overhead and capital costs) based on the costs actually incurred in Namutumba. We converted all base costs to 2020 US dollars using the Bureau of Economic Analysis implicit price deflators for gross domestic product (online Supplementary Table 1).

We then extrapolated those base costs to all other rural districts in Uganda via a set of extrapolation indices defined relative to Namutumba. The extrapolation indices were: (1) a spatial index based on the area of each district relative to Namutumba, (2) a child population index based on



the number of eligible children per district, (3) a VHT population index based on the number of VHTs per district and (4) a VHT-child population index based on the ratio of VHTs to eligible children per district compared to Namutumba (online Supplementary Figure 1). We used these indices to generate district-specific costs for each rural district that reflected differences in each district relative to Namutumba that would likely impact costs. For example, we assumed the cost of transport required for capacity building activities would vary based on the area of each district, so if the area of Namutumba was approximately 820 km<sup>2</sup> and the area of another rural district was approximately 1585 km<sup>2</sup>, the index for that district was defined as (1585/820) = 1.93 and the cost for transport associated with capacity building in that district was 1.93 times higher than in Namutumba District.

### **Effectiveness**

The effectiveness model was designed to estimate annual deaths averted and annual cases of moderate or severe anaemia, developmental disability, stunting and wasting averted attributable to SQ-LNS over a 10-year time horizon (Table 1). The model was also used to estimate DALYs averted, as described below. We applied the effect of SQ-LNS on each of these outcomes to specific age bands depending on the expected timing of effects relative to supplementation. We applied mortality, stunting and wasting reductions through the full period of supplementation (6–18 months of age). We applied reductions in moderate and severe anaemia from 9 to 24 months of age, assuming that changes in anaemia status would become evident after ~3 months of supplementation and would persist for 6 months post-supplementation. Finally, we modelled the onset in reductions in developmental disability during the 18- to 24-month age range. We used the Lives Saved Tool (LiST) population projections and the UN World Urbanisation Prospects to estimate rural child populations in 2022–2031 (online Supplementary Table 2).

For each outcome, modelled effectiveness of the intervention was calculated as the baseline prevalence of the adverse outcome, multiplied by the relative reduction as a result of SQ-LNS, multiplied by the relevant population size. The baseline mortality rate (~1.22%) was based on LiST subnational projections of mortality among rural Ugandan children age 6–11 months plus half of projected mortality among rural children 12–23 months (Table 1). We used data from the most recent Malaria Indicator Survey (2018–2019) to estimate the baseline prevalence of moderate and severe anaemia among rural children 6–9 months (59%), 9–18 months (41%) and 18–24 months (31%)<sup>(13)</sup>. The baseline prevalence of developmental disability of 6.6% was based on the estimate of 10% prevalence of developmental disability among children

under 5 years of age in low- and middle-income countries<sup>(14)</sup> multiplied by the predictive validity of 65.6% for a score in the lowest decile of the early childhood MacArthur–Bates Communicative Development Inventories to predict later language delay<sup>(15)</sup> (the Communicative Development Inventory was the most commonly used tool to assess the effect of SQ-LNS on language development among the studies in the most recent meta-analysis of SQ-LNS)<sup>(4)</sup>. We used data from the 2016 Uganda Demographic and Health Survey to estimate the baseline prevalence of stunting of 42%<sup>(16)</sup>. For wasting, we used a cross-sectional prevalence of 7.8% based on data from the 2016 Demographic and Health Survey<sup>(16)</sup>. We also estimated a lower and upper bound for the longitudinal prevalence of wasting by applying correction factors of 2.6 (calculated following UNICEF<sup>(17)</sup>) and 6 (from Barba, Huybregts and Leroy<sup>(18)</sup>), respectively, to the cross-sectional baseline prevalence.

We modelled a 27% relative reduction in mortality based on a meta-analysis of randomised controlled trials assessing the impact of SQ-LNS on all-cause mortality in children 6–24 months<sup>(3)</sup>. Relative reductions in moderate-to-severe anaemia (28%), developmental delay, i.e. scoring in the lowest decile for language (16%), stunting (12%) and cross-sectional prevalence of wasting at endline (14%) were based on individual participant data meta-analyses<sup>(2)</sup>. The SQ-LNS meta-analyses also demonstrated relative reductions in developmental delay for motor (16%) and socio-emotional development (19%), but to be conservative we chose to use only one of these domains (language) because there is overlap among these three outcomes and there is evidence for predictive validity of the language development assessment tool most commonly used in the SQ-LNS trials, as explained above. We modelled a 30% relative reduction in longitudinal prevalence of wasting based on findings from a cluster randomised controlled trial in Mali<sup>(19)</sup>, assuming that the impacts of SQ-LNS would be similar in Uganda.

We estimated DALYs as the sum of years of life lost due to mortality and years lived in disability due to moderate or severe anaemia and developmental disability. Years of life lost and years lived in disability were calculated as the product of cases of disability, the duration of disability and the disability weight (Table 1). We did not apply age weighting. DALYs averted were calculated as the difference in DALYs with and without the SQ-LNS intervention. We did not include stunting or wasting in our DALY estimates because stunting is not included as a disability in the 2019 GBD study, and the disability weight for moderate wasting without oedema is zero. Mild anaemia was not included because estimates of the impact of SQ-LNS on reductions in the prevalence of mild anaemia alone were not available from the meta-analyses, and the disability weight for mild anaemia was close to zero (0.004).

**Table 1** Effectiveness modelling parameter values and data sources

Disability	Baseline prevalence (rural population)	Baseline prevalence source	Relative reduction	Relative reduction source	Disability weight	Disability weight source	Duration of disability	Duration of disability source
Mortality	~1.22 %	LiST projections for rural 6–11 months mortality plus half* of rural 12–23 months mortality	27 %	Stewart <i>et al.</i> <sup>(3)</sup>	1	n/a	61 years	United Nations <sup>(59)</sup> Uganda life expectancy (63 years) minus onset at 2 years of age
Moderate or severe anaemia (Hb < 100 g/l)	6–9 months: 59 % 9–18 months: 41 % 18–24 months: 31 %	Uganda National Malaria Control Division (NMCD), Uganda Bureau of Statistics (UBOS) and ICF <sup>(13)</sup>	28 %	Dewey <i>et al.</i> <sup>(2)</sup>	0.055†	Global Burden of Disease Collaborative Network <sup>(60)</sup>	1.25 years	Based on assumed effect during 9 months of the 12-month intervention period (9–18 months) plus expected carry-over effect for 6 months post-intervention
Developmental disability	6.6 %‡	Global Research on Developmental Disabilities Collaborators <sup>(14)</sup> ; Sim <i>et al.</i> <sup>(15)</sup>	16 %	Dewey <i>et al.</i> <sup>(2,4)</sup>	0.011§	Global Burden of Disease Collaborative Network <sup>(60)</sup>	61 years	United Nations <sup>(59)</sup> Uganda life expectancy (63 years) minus onset at 2 years of age
Stunting (length-for-age < -2 SD)	42 %	Uganda 2016 DHS among children 24 months of age (rural population)	12 %	Dewey <i>et al.</i> <sup>(2)</sup>	n/all	n/a	n/a	n/a
Wasting (weight-for-age < -2 SD)	7.8 %¶ 20.3–46.8 %**	Uganda 2016 DHS among children 6–18 months of age (rural population)	14 %¶ 30 %**	Dewey <i>et al.</i> <sup>(2)</sup> ; Huybregts <i>et al.</i> <sup>(19)</sup>	n/all	n/a	n/a	n/a

DHS, Demographic and Health Survey; GBDS, Global Burden of Disease; LiST, Lives Saved Tool; MIS, Malaria Indicators Survey.

\*Assumes mortality uniformly distributed among children 12–23 months.

†Calculated as a weighted average of the disability weights for moderate (0.052) and severe (0.149) anaemia weighted by the prevalence of moderate and severe anaemia in the target population.

‡Calculated as developmental disability for children under 5 years of age (10 %) × 65.6 % predictive validity.

§Disability weight for borderline idiopathic developmental intellectual disability.

¶Stunting and wasting excluded from DALY calculation (stunting not included as a disability in the 2019 GBD study; disability weight for moderate wasting with or without oedema = zero).

¶¶Cross-sectional prevalence; relative reduction of 14 % based on Dewey *et al.*<sup>(2)</sup>.

\*\*Lower and upper bound longitudinal baseline values estimated by applying correction factors of 2.6 (calculated following UNICEF<sup>(17)</sup>) and 6 (from Barba, Huybregts and Leroy<sup>(18)</sup>), respectively, to cross-sectional prevalence; relative reduction of 30 % based on data for Mali<sup>(19)</sup>.



### Discounting

We calculated costs, effectiveness and cost-effectiveness under two scenarios. The first assumed a discount rate of zero following the recommendation in Murray *et al.*<sup>(20)</sup> and the second a discount rate of 3% as recommended in WHO<sup>(21)</sup> and Sanders *et al.*<sup>(22)</sup>. A discount rate greater than zero implies that costs and effects incurred in the future have a lower value than those same costs and effects had they been incurred today. Discounted DALY averted were calculated following Fox-Rushby and Hanson<sup>(23)</sup> without age weighting.

### Sensitivity analyses

We conducted several analyses to evaluate the sensitivity of our results to key assumptions and influential parameter values. First, based on the result of a sensitivity analysis scenario in Stewart *et al.*<sup>(3)</sup> in which passive control arms were excluded from the analysis, we modelled a scenario in which the relative reduction in mortality was 18% rather than 27%. We also modelled several different cost scenarios that included (1) elimination of the customs clearance costs for SQ-LNS, (2) a 10% decrease in the price of SQ-LNS, (3) an increase in the price of SQ-LNS from \$0.06 per sachet to \$0.09 per sachet (2020 USD) to reflect the current, updated price of SQ-LNS according to the UNICEF supply catalog, (4) lower VHT monetary incentives (reduced from \$0.44 to \$0.29 per delivery of SQ-LNS) or (5) higher VHT monetary incentives (increased from \$0.44 to \$0.87 per delivery of SQ-LNS). We also modelled 'best' and 'worst' case scenarios in which sensitivity analyses parameter values that would improve the cost-effectiveness of SQ-LNS were modelled simultaneously and those that would reduce cost-effectiveness were modelled simultaneously.

### Patient and public involvement

Because our study was based on secondary data, there was no patient or public involvement in this research.

## Results

### Costs

The estimated annual average cost of providing SQ-LNS for 12 months to all children starting at age 6 months in rural

districts of Uganda via the VHT system was ~\$58.7 million (2020 US dollars) or \$52 per child (Table 2; online Supplementary Table 3 for costs by year). Approximately \$22 of the total cost per child was the cost of the product, ~\$11 was international shipping and handling, customs clearance and domestic transport, storage and handling, and ~\$19 was non-product programmatic costs. The cost of the product represented the highest share of the total annual average cost (42.5%), followed by international shipping and handling and customs clearance for SQ-LNS (18.7%), capacity building (15.3%) and logistics (6%) (Figure 1).

### Effects and cost-effectiveness

We estimated that the provision of SQ-LNS in rural Uganda could avert an annual average of 242 292 DALYs as a result of 3689 annual child deaths averted, over 160 000 cases of moderate or severe anaemia averted and almost 6000 cases of developmental disability averted (Table 3). In addition, we estimated that SQ-LNS could annually avert an average of 55 858 cases of stunting, over 12 000 cases of wasting based on cross-sectional estimates and between 68 040 and 157 015 cases of wasting based on longitudinal estimates.

We estimated that the undiscounted cost-effectiveness of SQ-LNS over the 10-year intervention time horizon was \$242 per DALY averted or \$413 per DALY averted with costs and effects discounted at 3% (Table 3). For individual outcomes, undiscounted cost-effectiveness ranged from \$366 per case of moderate-to-severe anaemia averted to \$15 914 per death averted.

In the sensitivity analyses (Figure 2), the undiscounted cost per DALY averted ranged from \$195–\$448 under the best- and worst-case scenarios, and the cost per death averted ranged from \$12 823 to \$30 472. The cost per DALY averted and per death averted was most sensitive to changing the assumed mortality reduction from 27% to 18%.

## Discussion

In this study, we developed a framework for modelling the cost and cost-effectiveness of providing SQ-LNS to young

**Table 2** Estimated cost and cost-efficiency of providing daily SQ-LNS to all children in rural Uganda (2020 US dollars)

Cost basis	Product cost	Product shipping, taxes and domestic transport cost*	Non-product programmatic cost	Total cost
Per sachet	\$0.06	\$0.03	\$0.05	\$0.14
Per child†	\$22.32	\$11.05	\$19.13	\$52.49
Average per year (all children)‡,§	\$24 959 289	\$12 352 734	\$21 390 199	\$58 702 222

SQ-LNS, small-quantity lipid-based nutrient supplement.


\*Product shipping, taxes and domestic transport include the cost of international shipping and handling, customs clearance and domestic transport, storage and handling.

†Assuming daily supplementation for 12 months.

‡Based on providing SQ-LNS to an average of 1 118 340 children per year.

§Average cost per year on the basis of non-product programmatic cost and total cost include annualised start-up costs.





**Fig. 1** Estimated average annual cost, by activity, of daily provision of SQ-LNS to all children aged 6–18 months in rural Uganda delivered via village health teams. Costs in millions of 2020 US dollars. M&E, monitoring and evaluation; SQ-LNS, small-quantity lipid-based nutrient supplements; S&H, shipping and handling; VHT, village health team

**Table 3** Estimated effectiveness and cost-effectiveness of providing daily SQ-LNS to all children in rural Uganda

Outcome	Annual average effectiveness over 10 years of intervention	Undiscounted cost-effectiveness*, †	Discounted cost-effectiveness*, ‡
DALY averted	242 202	\$242	\$413
Deaths averted	3689	\$15 914	\$15 538
Cases of anaemia averted	160 267	\$366	\$357
Cases of developmental disability averted	5905	\$9941	\$9684
Cases of stunting averted	55 828	\$1051	\$1024
Cases of wasting averted (14% RR)	12 212	\$4807	\$4683
Cases of wasting averted (30% RR)§	68 040–157 015	\$374–\$863	\$364–\$840

SQ-LNS, small-quantity lipid-based nutrient supplement; DALY, disability-adjusted life year; RR, relative reduction.

\*All estimates of cost-effectiveness presented in 2020 US dollars.

†Cost-effectiveness (cost per unit of effectiveness) over modelled intervention period of 2021–2031.


‡Discounted cost-effectiveness estimates based on discounting both costs and effects at 3%.

§Based on lower and upper bound longitudinal prevalence of wasting estimates of 20.3% and 46.8%

children in rural Uganda, a framework that can be adapted and used to make similar sets of estimates in other countries. We estimated that the economic cost of providing SQ-LNS to all children for 12 months, from 6 to 18 months of age, in rural Uganda would be ~\$52 per child (2020 US dollars). Cost-effectiveness estimates were \$15 914 per death averted and \$242 per DALY averted (undiscounted) or \$413 per DALY averted with costs and effects discounted at 3%. Although there is no consensus on a specific cost-effectiveness threshold, the WHO has suggested that interventions with a cost per DALY averted less than gross domestic product per capita may be considered very cost-effective<sup>(24)</sup>. Per capita gross domestic product was \$822 in Uganda in 2020<sup>(25)</sup>, so SQ-LNS would

be classified as very cost effective. It is important to note, however, that this classification of cost-effectiveness does not imply affordability or policy feasibility. To this point, the estimated average annual cost of the programme (~\$58.7 million US dollars, Table 2) represents a substantial share of Uganda’s total health budget, which was UGX2,718 billion in 2021/2022 or ~\$75 million (2020 USD based on the average 2020 exchange rate)<sup>(26)</sup>. We discuss possible strategies for sharing and/or reducing costs below.

These results should be interpreted in the context of study strengths and limitations. One strength was the ability to model costs based on cost estimates adapted from a comprehensive costing study of MNP in Uganda. This sets



**Fig. 2** Cost per disability-adjusted life year (DALY) averted (top panel) and cost per death averted (bottom panel) under each sensitivity analysis scenario. The best-case scenario simultaneously models the elimination of customs clearance costs, a 10% decrease in price of SQ-LNS, and lower VHT monetary incentives. The worst-case scenario simultaneously models an 18% mortality reduction, an increase in price of SQ-LNS (\$0.06 to \$0.09/sachet) and higher VHT monetary incentives. SQ-LNS, small-quantity lipid-based nutrient supplements; VHT, village health team

our study apart from many other efforts to model the cost and cost-effectiveness of nutrition interventions that rely on generic unit cost estimates. In addition, our estimates of effects were based on direct evidence of the impact of SQ-LNS on each outcome from recent meta-analyses that included 14–18 randomised controlled trials (mostly in Sub-Saharan Africa) that included a total of > 37 000 children. About half of these trials were conducted within existing community-based or clinic-based programmes, so the results are relevant to real-world settings. Finally, we used the CHEERS 2022 checklist to ensure we met each relevant criterion for high-quality reporting of our methods and results<sup>(27)</sup>. Because Uganda was not one of the sites in which the trials of SQ-LNS were conducted, one study limitation is that we had to assume that the findings of the meta-analyses would apply to Uganda. Another limitation

is that we were not able to estimate costs and cost-effectiveness in urban settings due to the lack of information on the cost of delivering a product like SQ-LNS via platforms that are prevalent in urban areas such as routine health clinic services. As a result, there is uncertainty around the extent to which these results would apply to urban settings or to settings in other countries in which a delivery platform like Uganda’s VHT system does not exist. There is also some uncertainty regarding the estimates for developmental disability because we based this outcome on persistent language difficulty, which contributes to but is not a direct measure of intellectual disability. However, we may also have underestimated the impact on developmental delay because we based our estimates only on language delay even though the SQ-LNS meta-analyses also documented reductions in delayed



motor and socio-emotional development. Finally, there is some evidence from low- and middle-income countries that interventions providing Fe to children can heighten the risk of malaria<sup>(28)</sup> and diarrhoea<sup>(29,30)</sup>. While evidence from randomised controlled trials from multiple low- and middle-income countries has shown that SQ-LNS does not increase the risk of fever or suspected malaria mortality<sup>(31–35)</sup>, and trials in Bangladesh have shown that SQ-LNS reduces the prevalence of diarrhoea<sup>(36)</sup> and the duration of diarrhoea, pneumonia and dysentery<sup>(37)</sup>, it is theoretically possible that consuming SQ-LNS could have negative side-effects, including increased risk of infection. Any costs to caregivers associated with such side-effects, including medical expenses and the opportunity cost of caregivers' time caring for sick children, were not accounted for in our analysis.

We are aware of only one other published study that estimated the cost of providing SQ-LNS to children. Hiebert *et al.*<sup>(38)</sup> estimated the cost of including daily SQ-LNS for children 6–23 months of age as part of an integrated package of maternal and child interventions in rural Niger. They found that the incremental cost of adding 18 months of SQ-LNS delivery per child to the standard of care (interventions that were already being delivered) was \$44 per child (\$29/year) (2019 US dollars), though this cost was based only on the cost of the product plus freight and is therefore not comparable to our total cost estimates.

In addition to the cost study of MNP from which our cost estimates were derived<sup>(8)</sup>, several studies have modelled the cost and cost-effectiveness of providing various nutrition interventions to young children in Uganda, including Pasricha *et al.*<sup>(39)</sup> who estimated the cost-effectiveness of MNP supplementation, and Shekar *et al.*<sup>(40)</sup> who estimated the cost-effectiveness of providing complementary food. Several key methodological choices complicate the direct comparison of results across studies. For estimating costs, the chosen perspective and type of costing can significantly influence cost estimates. Cost studies conducted from a societal perspective, as is the case for our study, account for the economic value of all resources used in providing and accessing an intervention for *all* stakeholders. Cost studies conducted from a narrower perspective, for example, from the perspective of programme implementers or the government, are limited to the costs incurred only by those stakeholders. Similarly, cost studies using economic costing are comprehensive in that all inputs used in providing and accessing an intervention are included, even inputs that are not paid for such as volunteer labour or household time to participate in an intervention, in which case the economic cost of the input is the input's value in its next best use (i.e. the input's opportunity cost)<sup>(21)</sup>. This can lead to very different estimates of cost than is the case in studies based only on financial costs, which exclude opportunity costs. These and other intervention characteristics that can influence costs estimates are summarised, by study, in

Table 4. After adjusting for differences in study characteristics where possible, estimates from other studies ranged from \$22 per child to deliver MNP to \$72 per child for the provision of complementary food. Our estimate of \$52 per child for SQ-LNS falls within this range. There was wide variation in the percentage of the total cost per child attributed to the cost of the product itself, ranging from 18% for MNP based on the Schott *et al.*<sup>(8)</sup> study to 77% for complementary food (note that, for the provision of complementary food, although the cost of the food itself is high, it is also possible that the programme would generate local economic benefits if locally produced foods are chosen, although smaller-scale production may lead to higher food prices, potentially offsetting some local economic benefits). Our model indicated that product costs represent 42% of the cost of delivering SQ-LNS. If non-product costs of nutrition interventions are underestimated, cost-effectiveness estimates may be overly optimistic.

Differences in the methodology used to model the effects of an intervention can also make it difficult to directly compare estimates of cost-effectiveness. The approach we took, which was also taken by Pasricha *et al.*<sup>(39)</sup>, was to use direct effects of a specific intervention for all modelling based on systematic reviews of randomised controlled trials of that intervention. This is in contrast to the approach employed by the Investments Framework for Nutrition work<sup>(41)</sup>, including the Shekar *et al.*<sup>(40)</sup> Uganda study, in which estimated effects of interventions on diseases (morbidity), anaemia, wasting and stunting based on systematic reviews of similar interventions were inserted into the LiST model to estimate lives saved and other outcomes. The LiST pathways for mortality are defined via cause-specific mortality, which means that the impacts of complementary feeding interventions on child mortality are estimated based on effects on specific diseases, stunting and wasting<sup>(42)</sup>. Our model used direct effects of SQ-LNS on all-cause mortality; we did not have data on cause-specific mortality. Our estimated undiscounted cost per DALY averted was \$242 for SQ-LNS, considerably lower than the estimates for MNP (\$3877) and provision of complementary food (\$720) in Uganda (Table 4). Our estimated undiscounted cost per death averted was \$15 914 for SQ-LNS, much lower than the estimate of \$47 365 for provision of complementary food; there is no estimate for MNP because no effect of MNP on mortality has been documented<sup>(43)</sup>. However, it is important to bear in mind that variation in the approaches to cost and effectiveness modelling across these studies could account for some of these differences.

As mentioned, our models assumed that all children would be provided with SQ-LNS for 12 months starting at 6 months of age. We made this assumption because most of the randomised trials in the meta-analyses started SQ-LNS at 6 months and provided the supplements for at least 12 months, so our estimates of effects are mostly relevant to





**Table 4** Study-specific costing characteristics and cost, adjusted\* cost and cost-effectiveness estimates

		This study	Schott <i>et al.</i> 2021	Pasricha <i>et al.</i> 2020	Shekar <i>et al.</i> 2016
Cost study characteristics	Geography	Rural Uganda	1 rural district of Uganda	Uganda	Uganda
	Product, frequency	SQ-LNS, daily	MNP, every other day	MNP, daily	Complementary food (~250 kcal), daily
	Target population	Children 6–18 months	Children 6–24 months	Children 6–12 months	Subset of children 6–24 months
	Duration of intervention	12 months	18 months	6 months	Not specified
	Coverage	100 %	64 %†	100 %	100 %
Cost estimates	Costing perspective	Societal	Societal	Programme implementers	Programme implementers
	Type of costing	Economic	Economic	Financial	Financial
	Cost per child‡	52	39	11	72§
	Product/food cost per child	22	7	6	56
	Non-product/food cost per child	30	32	5	17
Adjusted cost estimates	Product/food cost as percentage of total cost per child	42 %	18 %	55 %	77 %
	Cost per child‡	52	34	22	72§
	Product/food cost per child	22	10	12	56
	Non-product/food cost per child	30	24	10	17
	Product/food cost as percentage of total cost per child	42 %	30 %	55 %	77 %
Cost-effectiveness	Disabilities included in DALY calculation	Anaemia, developmental disability, mortality	n/a	Anaemia, malaria¶, diarrhoea¶¶, mortality¶¶	Mortality, stunting**
	Cost per DALY averted‡	242	n/a	3877	720
	Cost per death averted	15 914	n/a	n/a	47 365

DALY, disability-adjusted life year; MNP, micronutrient powder; SQ-LNS, small-quantity lipid-based nutrient supplements.

\*Costs adjusted to estimate the cost per child of daily supplementation for 12 months at 100 % coverage. For Schott *et al.*, product/food costs adjusted by multiplying reported unit cost per packet (30 sachets) of MNP by 12 months, and adjusted non-product costs estimated based on (1) increased 'last mile' VHT/HW and household opportunity costs to account for additional MNP deliveries and (2) higher total product shipping and import duty costs. For Pasricha *et al.*, product/food costs adjusted by multiplying reported unit cost per sachet by 365 d, and non-product costs calculated by assuming the ratio of food to non-food costs would remain the same. Because unit costs in Shekar *et al.* were already defined based on daily supplementation for 12 months, no adjustment was necessary.

†Based on reach, defined as consumption of MNP in past 7 d. Costs per child based on the subset of reached children. If instead costs per child were on the basis of all targeted children, the cost per child would be \$25, the product cost per child would be \$4, the non-product cost per child would be \$20 and the product cost as a percentage of the total cost would be 17 %.

‡All costs in undiscounted 2020 US dollars.

§The cost per child is based on the annual cost of supplementation (supplementation for 12 months), not supplementation from 6 to 24 months.

¶Potential increase or decrease in malaria and mortality attributable to MNP.

¶¶Potential increase in diarrhoea attributable to MNP.

\*\*The projected number of lives saved and cases of childhood stunting averted were calculated using the Lives Saved Tool (LiST).



this scenario. In real-world programmes, children may begin receiving SQ-LNS later than 6 months, and duration of supplementation might vary. These variables would affect both costs and effectiveness. There is currently insufficient evidence to estimate effectiveness for scenarios in which the age at beginning of supplementation and duration of access to SQ-LNS vary. This is an important gap and is a high priority for further research.

In real-world programmes, adherence to the recommended daily consumption of SQ-LNS can also be highly variable. The trials in the SQ-LNS meta-analysis defined adherence in very different ways, so no overall estimate is available. In the programme-based trials, the lowest estimate was 37%<sup>(44)</sup>, based on caregiver receipt of SQ-LNS in the previous month, and the highest estimate was 97.4%<sup>(45)</sup>, based on the percentage of caregivers reporting 'high adherence' (child consumption > 4 d/week). In three other programme-based trials, average adherence was 47%<sup>(19)</sup>, 73.5%<sup>(32)</sup> and 97%<sup>(46)</sup>. Thus, our effectiveness estimates do not assume 100% adherence. Moreover, average study-level adherence generally did not modify the effect of SQ-LNS in the meta-analysis<sup>(2)</sup>. We thus believe that our effectiveness estimates are robust with regard to variation in adherence.

Our model was based on a community-based platform in which CHWs would deliver SQ-LNS every 3 months. More frequent delivery (e.g. every month) would increase costs somewhat, probably similar to the cost increment we modelled for providing a higher VHT incentive in the sensitivity analyses. There is wide variability across and within countries in the performance of CHW/VHT systems, which will influence cost-effectiveness. Some programmes may need strengthening to adequately deliver SQ-LNS. On the other hand, the addition of a supplement to be provided by CHW to caregivers may enhance CHW performance. For example, in Bangladesh<sup>(45)</sup>, CHWs were more likely to conduct the intended monthly home visits when they had a supplement to deliver. Additional implementation science research to evaluate the programmatic impact of adding delivery of supplements such as SQ-LNS to the usual activities of CHWs would be useful.

There are other potential platforms for distribution of SQ-LNS that warrant cost-effectiveness modelling, including provision via health clinics. The integration of SQ-LNS provision into existing programmes for wasting prevention and treatment has been evaluated in a health system platform in Burkina Faso<sup>(44)</sup> and a CHW platform in Mali<sup>(19)</sup>. In both sites, provision of SQ-LNS was a powerful incentive for caregivers to attend monthly screenings for acute malnutrition. If there are cost savings associated with reduced need for treatment for moderate or severe acute malnutrition and for hospitalisation, this can be factored into economic analyses of SQ-LNS. Further work is also needed to evaluate the impact of providing SQ-LNS as an incentive to attend health clinics and/or social and behaviour change communication sessions, with regard

to potentially increased uptake of non-nutrition services such as immunisations.

Although our results suggest that provision of SQ-LNS is highly cost-effective, the total cost for a programme aimed at all age-eligible children in a given country is high. This is inherent to a food-based intervention that is designed for prevention (rather than treatment) of malnutrition, such as blanket provision of complementary foods. Cost-sharing arrangements in which households or other stakeholders have been called upon to pay some of the cost of goods and services provided to children are not uncommon. Previous work to estimate willingness-to-pay for SQ-LNS from several countries in Sub-Saharan Africa suggests that, across countries and methods of eliciting willingness-to-pay (including hypothetical (money did not change hands) and experimental (money changed hands)), average willingness-to-pay for SQ-LNS is above the product price of \$0.06 per sachet<sup>(47–49)</sup>. If some rural Ugandan households were willing to cover the cost of SQ-LNS, financing needs for those children would drop to ~\$30 per child, although shifting costs from implementing agencies to households does not change the total societal cost of the intervention.

Although financing needs could be greatly reduced if households covered some or all of the cost of the product, SQ-LNS cost-sharing strategies would need to account for the fact that, in many settings, most households cannot afford to pay the full price of the product. For example, evidence from a market trial in Burkina Faso suggests that, in that context, household persistent demand for SQ-LNS was very limited<sup>(50)</sup>. In addition, expecting households to cover the cost of the product could substantially limit uptake and/or consistent use over time, which has been observed in other settings for preventative health products<sup>(51)</sup> and would likely have unquantified negative implications for the effectiveness of SQ-LNS on our outcomes of interest. Developing a cost-sharing distribution strategy in which households with the ability to pay are expected to pay while poorer households are provided SQ-LNS free of charge through a voucher system, for example, might be a possibility. This would require research into the cost and feasibility of mechanisms for identifying households who could and could not pay, complemented by research on demand for SQ-LNS, uptake and consistency of use and benefits under a targeted voucher system. This would provide an empirical basis upon which the cost-effectiveness of such a strategy could be modelled.

Another option for reducing costs would be to target the intervention to the most vulnerable communities, such as those with high levels of stunting, wasting, child mortality or food insecurity. For instance, in Uganda, SQ-LNS could be targeted to rural districts in sub-regions with the highest rates of child mortality. According to the 2016 Demographic and Health Survey, of the fifteen sub-regions represented in the survey, the worst-off sub-regions in



terms of child mortality were West Nile, Busoga, Tooro, Ankole and Karamoja<sup>(52)</sup>. By matching rural districts to these five sub-regions, we estimated that, if targeting were based on child mortality rates, approximately 35 % of children 6–18 months of age in rural Uganda would receive SQ-LNS (396 808 annual average children compared to 1 118 340 children under the untargeted scenario). While the cost per child would still be ~\$52, assuming that the targeting could be accomplished with existing, regularly collected data (if community-level targeting required new data collection, the cost per child would increase), the annual average cost of the programme would drop by ~65 % (from ~\$58.7 million to ~\$20.8 million per year). In addition to reducing costs, targeting SQ-LNS to children in the most vulnerable communities could enhance effectiveness for certain outcomes. In the SQ-LNS meta-analyses, the impacts of SQ-LNS on development and Fe status were greater among children with a higher burden of under-nutrition or lower socio-economic status<sup>(4,6)</sup>. Note that the cost of individual-level targeting, which would involve screening children, could be substantial, so targeting at the community-level rather than the individual-level is generally more feasible.

### Conclusion

Despite increased focus on early childhood malnutrition over the past decade, millions of children in low- and middle-income countries remain vulnerable to under-nutrition<sup>(53–55)</sup>. Strategies that include provision of supplements such as SQ-LNS have been shown to be effective in helping reduce this burden. However, making informed policy decisions aimed at developing a portfolio of effective, cost-effective and financially feasible interventions requires that robust estimates of intervention programme costs and cost-effectiveness be available to policymakers and programme planners alongside evidence of effectiveness.

Investing in SQ-LNS has the potential to cost-effectively save child lives and to avert cases of anaemia, developmental disability, stunting and wasting, but the total cost of programmes that include SQ-LNS can be substantial. Financing strategies may require innovative financing mechanisms based on stakeholders' recognition that such programmes will enhance child welfare and make fundamental contributions to reducing poverty and promoting overall economic development over the long term. This approach has been used for other types of investments, such as early childhood education programmes, which contribute to an array of development objectives<sup>(56)</sup> but are expensive to establish and to maintain; indeed, multiple stakeholders are generally called upon to fund early childhood education programmes<sup>(57)</sup>. For their part, households recognise these benefits, some of which accrue to them, and are willing to pay for them<sup>(58)</sup>, but requiring resource-poor households to

do so can raise equity issues. Similarly, for programmes that include SQ-LNS, households may be willing to cover some of the costs<sup>(47)</sup>, though more research is needed on household demand persistence<sup>(50)</sup>. If policymakers choose to invest in SQ-LNS, sustainably financing its incorporation into portfolios of child nutrition interventions may require targeting and/or other strategies to reduce and spread costs among multiple stakeholder groups.

### Acknowledgements

The authors gratefully acknowledge Robert Ackatia-Armah for his guidance on the development of the cost model and for providing important Uganda-specific context. We also thank Belinda Richardson and Emily Baker for guiding us through the Uganda MNP costing study data. We also gratefully acknowledge the coordinating support of Caroline Joyce.

### Financial support

This work was supported, in whole or in part, by a grant from the Bill & Melinda Gates Foundation (OPP49817) to the University of California, Davis. Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission.

### Conflicts of interest

All authors declare they have no conflicts of interest.

### Authorship

K.G.D. conceptualised the study. All authors designed the study. K.P.A. and S.A.V. developed the cost model. K.P.A. and C.D.A. developed the effectiveness model. K.P.A. and K.G.D. wrote the first draft of the manuscript. All authors contributed to data interpretation and revisions of the manuscript, and read and approved the final manuscript.

### Ethics of human subject participation

Not applicable.

### Supplementary material

For supplementary material accompanying this paper visit <https://doi.org/10.1017/S1368980023001805>



## References

1. Arimond M, Zeilani M, Jungjohann S *et al.* (2015) Considerations in developing lipid-based nutrient supplements for prevention of undernutrition: experience from the International Lipid-Based Nutrient Supplements (iLiNS) project. *Matern Child Nutr* **11**, 31–61.
2. Dewey KG, Stewart CP, Wessells KR *et al.* (2021) Small-quantity lipid-based nutrient supplements for the prevention of child malnutrition and promotion of healthy development: overview of individual participant data meta-analysis and programmatic implications. *Am J Clin Nutr* **114**, 3S–14S.
3. Stewart CP, Wessells KR, Arnold CD *et al.* (2019) Lipid-based nutrient supplements and all-cause mortality in children 6–24 months of age: a meta-analysis of randomized controlled trials. *Am J Clin Nutr* **111**, 207–218.
4. Prado EL, Arnold CD, Wessells KR *et al.* (2021) Small-quantity lipid-based nutrient supplements for children age 6–24 months: a systematic review and individual participant data meta-analysis of effects on developmental outcomes and effect modifiers. *Am J Clin Nutr* **114**, 43S–67S.
5. Das JK, Salam RA, Hadi YB *et al.* (2019) Preventive lipid-based nutrient supplements given with complementary foods to infants and young children 6 to 23 months of age for health, nutrition, and developmental outcomes. *Cochrane Database Syst Rev* issue 5, CD012611.
6. Wessells KR, Arnold CD, Stewart CP *et al.* (2021) Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child anemia and micronutrient status: an individual participant data meta-analysis of randomized controlled trials. *Am J Clin Nutr* **114**, 68S–94S.
7. Keats EC, Das JK, Salam RA *et al.* (2021) Effective interventions to address maternal and child malnutrition: an update of the evidence. *Lancet Child Adolesc Health* **5**, 367–384.
8. Schott W, Richardson B, Baker E *et al.* (2021) Comparing costs and cost-efficiency of platforms for micronutrient powder (MNP) delivery to children in rural Uganda. *Ann NY Acad Sci* **1502**, 28–39.
9. Mays DC, O'Neil EJ Jr, Mworozzi EA *et al.* (2017) Supporting and retaining village health teams: an assessment of a community health worker program in two Ugandan districts. *Int J Equity Health* **16**, 129.
10. Ferris D (2019) *Landscape Analysis on Uganda's Readiness to Distribute Micronutrient Power 'Sprinkles': Desk Analysis of Country Readiness*. Uganda: BRAC Independent and Evaluation Cell; available at <https://thedocs.worldbank.org/en/doc/371201594662388378-0090022020/original/TF0A96441UgandaMNPAssessmentFINAL002.pdf> (accessed June 2022).
11. Turinawe EB, Rwemisisi JT, Musinguzi LK *et al.* (2015) Selection and performance of village health teams (VHTs) in Uganda: lessons from the natural helper model of health promotion. *Hum Resour Health* **13**, 73.
12. Zheng CY, Musominali S, Chaw GF *et al.* (2019) A performance-based incentives system for village health workers in Kisoro, Uganda. *Ann Glob Health* **85**, 46.
13. Uganda National Malaria Control Division (NMCD), Uganda Bureau of Statistics (UBOS) & ICF (2020) *Uganda Malaria Indicator Survey 2018–2019 (dataset)*. Kampala, Uganda; Rockville, MD: NMCD, UBOS, and ICF. Ugkr7ifl. Dta
14. Global Research on Developmental Disabilities Collaborators (2018) Developmental disabilities among children younger than 5 years in 195 countries and territories, 1990–2016: a systematic analysis for the global burden of disease study 2016. *Lancet Glob Health* **6**, e1100–e1121.
15. Sim F, Thompson L, Marryat L *et al.* (2019) Predictive validity of preschool screening tools for language and behavioural difficulties: a PRISMA systematic review. *PLOS ONE* **14**, e0211409.
16. Uganda Bureau of Statistics (UBOS) & ICF (2018) *Uganda Demographic and Health Survey 2016. (dataset)*. Kampala, Uganda; Rockville, MD: UBOS and ICF. Ugpr7bfl. Dta.
17. UNICEF (2021) *Guidance for Estimating the Number of Children in Need of Treatment for Wasting*. New York: UNICEF Nutrition.
18. Barba FM, Huybregts L & Leroy JL (2020) Incidence correction factors for moderate and severe acute child malnutrition from 2 longitudinal cohorts in Mali and Burkina Faso. *Am J Epidemiol* **189**, 1623–1627.
19. Huybregts L, Le Port A, Becquey E *et al.* (2019) Impact on child acute malnutrition of integrating small-quantity lipid-based nutrient supplements into community-level screening for acute malnutrition: a cluster-randomized controlled trial in Mali. *PLoS Med* **16**, e1002892.
20. Murray CJL, Vos T, Lozano R *et al.* (2012) Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the global burden of disease study 2010. *Lancet* **380**, 2197–2223.
21. World Health Organization (2003) *Making Choices in Health: WHO Guide to Cost-Effectiveness Analysis*. Geneva, Switzerland: WHO.
22. Sanders GD, Neumann PJ, Basu A *et al.* (2016) Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. *JAMA* **316**, 1093–1103.
23. Fox-Rushby J & Hanson K (2001) Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. *Health Policy Planning* **16**, 326–331.
24. Commission on Macroeconomics and Health: *Investing in Health for Economic Development*. Geneva: World Health Organization; available at <http://www1.worldbank.org/publicsector/pe/PEAMMarch2005/CMHReport.pdf> (accessed January 2022).
25. World Bank (2022) World Bank National Accounts Data, and OECD National Accounts Data Files. <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=UG> (accessed February 2022).
26. UNICEF (2022) Uganda Budget Briefs 2022/23: Safeguarding Public Investments in Health in the Advent of COVID-19. UNICEF, Economic Policy Research Centre. <https://www.unicef.org/esa/documents/uganda-budget-briefs-2022-2023> (accessed May 2023).
27. Husereau D, Drummond M, Augustovski F *et al.* (2022) Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) explanation and elaboration: a report of the ISPOR CHEERS II good practices task force. *Value Health* **25**, 1.
28. Sazawal S, Black RE, Ramsan M *et al.* (2006) Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community-based, randomised, placebo-controlled trial. *Lancet* **367**, 133–143.
29. Soofi S, Cousens S, Iqbal SP *et al.* (2013) Effect of provision of daily zinc and iron with several micronutrients on growth and morbidity among young children in Pakistan: a cluster-randomised trial. *Lancet* **382**, 29–40.
30. Jaeggi T, Kortman GAM, Moretti D *et al.* (2015) Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. *Gut* **64**, 731–742.
31. Adu-Afarwuah S, Lartey A, Brown KH *et al.* (2007) Randomized comparison of 3 types of micronutrient supplements for home fortification of complementary foods in Ghana: effects on growth and motor development. *Am J Clin Nutr* **86**, 412–420.
32. Humphrey JH, Mbuya MNN, Ntozini R *et al.* (2019) Independent and combined effects of improved water,





sanitation, and hygiene, and improved complementary feeding, on child stunting and anaemia in rural Zimbabwe: a cluster-randomised trial. *Lancet Glob Health* **7**, e132–e147.

33. Null C, Stewart CP, Pickering AJ *et al.* (2018) Effects of water quality, sanitation, handwashing, and nutritional interventions on diarrhoea and child growth in rural Kenya: a cluster-randomised controlled trial. *Lancet Glob Health* **6**, e316–e329.
34. Fernald LC, Weber A, Galasso E *et al.* (2011) Socioeconomic gradients and child development in a very low income population: evidence from Madagascar. *Dev Sci* **14**, 832–847.
35. Prendergast AJ, Chasekwa B, Evans C *et al.* (2019) Independent and combined effects of improved water, sanitation, and hygiene, and improved complementary feeding, on stunting and anaemia among HIV-exposed children in rural Zimbabwe: a cluster-randomised controlled trial. *Lancet Child Adolesc Health* **3**, 77–90.
36. Luby SP, Rahman M, Arnold BF *et al.* (2018) Effects of water quality, sanitation, handwashing, and nutritional interventions on diarrhoea and child growth in rural Bangladesh: a cluster randomised controlled trial. *Lancet Glob Health* **6**, e302–e315.
37. Christian P, Shaikh S, Shamim AA *et al.* (2015) Effect of fortified complementary food supplementation on child growth in rural Bangladesh: a cluster-randomized trial. *Int J Epidemiol* **44**, 1862–1876.
38. Hiebert L, Phelan K, Kinda M *et al.* (2021) Costs of implementing an integrated package of maternal and pediatric interventions including SQ-LNS in rural Niger. *Food Nutr Bul* **42**, 567–583.
39. Pasricha S-R, Gheorghe A, Sakr-Ashour F *et al.* (2020) Net benefit and cost-effectiveness of universal iron-containing multiple micronutrient powders for young children in 78 countries: a microsimulation study. *Lancet Glob Health* **8**, e1071–e1080.
40. Shekar M, Hyder Z, Subandoro A *et al.* (2016) *An Investment Framework for Nutrition in Uganda: Reducing Stunting and Other Forms of Child Malnutrition. Health, Nutrition and Population (HNP) Discussion Paper*. Washington, DC: The World Bank.
41. Shekar M, Kakietek J, Eberwein JD *et al.* (2017) *An Investment Framework for Nutrition. Reaching the Global Targets for Stunting, Anemia, Breastfeeding, and Wasting*. Washington, DC: The World Bank; available at <https://elibrary.worldbank.org/doi/abs/10.1596/28499> (accessed January 2022).
42. Scott N, Delpont D, Hainsworth S *et al.* (2020) Ending malnutrition in all its forms requires scaling up proven nutrition interventions and much more: a 129-country analysis. *BMC Med* **18**, 356.
43. Suchdev PS, Jefferds MED, Ota E *et al.* (2020) Home fortification of foods with multiple micronutrient powders for health and nutrition in children under two years of age. *Cochrane Database Syst Rev* issue 2, Cd008959.
44. Becquey E, Huybregts L, Zongrone A *et al.* (2019) Impact on child acute malnutrition of integrating a preventive nutrition package into facility-based screening for acute malnutrition during well-baby consultation: a cluster-randomized controlled trial in Burkina Faso. *PLoS Med* **16**, e1002877.
45. Dewey KG, Mridha MK, Matias SL *et al.* (2017) Lipid-based nutrient supplementation in the first 1000 d improves child growth in Bangladesh: a cluster-randomized effectiveness trial. *Am J Clin Nutr* **105**, 944–957.
46. Iannotti LL, Dulience SJL, Green J *et al.* (2014) Linear growth increased in young children in an urban slum of Haiti: a randomized controlled trial of a lipid-based nutrient supplement. *Am J Clin Nutr* **99**, 198–208.
47. Adams KP, Vosti SA, Ayifah E *et al.* (2018) Willingness to pay for small-quantity lipid-based nutrient supplements for women and children: evidence from Ghana and Malawi. *Matern Child Nutr* **14**, e12518.
48. Segrè J, Winnard K, Abrha TH *et al.* (2015) Willingness to pay for lipid-based nutrient supplements for young children in four urban sites of Ethiopia. *Matern Child Nutr* **11**, 16–30.
49. Tripp K, Perrine CG, de Campos P *et al.* (2011) Formative research for the development of a market-based home fortification programme for young children in Niger. *Matern Child Nutr* **7**, 82–95.
50. Lybbert TJ, Vosti SA, Adams KP *et al.* (2018) Household demand persistence for child micronutrient supplementation. *J Health Econ* **62**, 147–164.
51. Cohen JL (2019) The enduring debate over cost sharing for essential public health tools. *JAMA Netw Open* **2**, e199810.
52. Uganda Bureau of Statistics (UBOS) & ICF (2018) *Uganda Demographic and Health Survey 2016*. Kampala, Uganda; Rockville, MD: UBOS and ICF.
53. UNICEF, World Health Organization & World Bank (2021) *Levels and Trends in Child Malnutrition: Key Findings of the 2021 Edition*. Geneva, Switzerland: World Health Organization; available at <https://www.who.int/publications/i/item/9789240025257> (accessed January 2022).
54. Sun J, Wu H, Zhao M *et al.* (2021) Prevalence and changes of anemia among young children and women in 47 low- and middle-income countries, 2000–2018. *eClinicalMedicine* **41**, 101136.
55. Black RE, Victora CG, Walker SP *et al.* (2013) Maternal and child undernutrition and overweight in low-income and middle-income countries. *Lancet* **382**, 427–451.
56. Psacharopoulos G & Woodhall M (1985) *Education for Development: An Analysis of Investment Choices*. Oxford: Oxford University Press for The World Bank.
57. Belfield CR (2006) Financing Early Childhood Care and Education: An International Review. UNESCO. <http://unesdoc.unesco.org/images/0014/001474/147443e.pdf> (accessed October 2022).
58. Gertler P & Glewwe P (1990) The willingness to pay for education in developing countries: evidence from rural Peru. *J Public Econ* **42**, 251–275.
59. United Nations, Department of Economic and Social Affairs & Population Division (2019) *World Population Prospects 2019*. Online Edition. Rev. 1. <https://population.un.org/wpp/Download/Standard/Mortality/> (accessed March 2021).
60. Global Burden of Disease Collaborative Network (2020) *Global Burden of Disease Study 2019 (GBD 2019) Disability Weights*. Seattle, WA: Institute for Health Metrics and Evaluation (IHME); available at <https://ghdx.healthdata.org/record/ihme-data/gbd-2019-disability-weights> (accessed January 2022).